Detalhe da pesquisa
1.
GPRC5D-Targeted CAR T Cells for Myeloma.
N Engl J Med
; 387(13): 1196-1206, 2022 09 29.
Artigo
Inglês
| MEDLINE | ID: mdl-36170501
2.
Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cellsâ©.
Clin Nephrol
; 93(1): 42-46, 2020 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-31670650
3.
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
Mol Ther
; 26(6): 1447-1456, 2018 06 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29678657
4.
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Mol Ther
; 26(8): 1896-1905, 2018 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29910179
5.
Endogenous CD28 drives CAR T cell responses in multiple myeloma.
bioRxiv
; 2024 Apr 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38562904
6.
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.
Leukemia
; 35(2): 506-521, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32447345
7.
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Front Immunol
; 12: 663379, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33936101
8.
Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Cancer Immunol Res
; 8(6): 743-755, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32209638
9.
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
Blood Cancer Discov
; 1(2): 146-154, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33089218
10.
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
Blood Adv
; 4(15): 3776-3787, 2020 08 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32780846
11.
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
Cancer Cell
; 35(3): 473-488.e6, 2019 03 18.
Artigo
Inglês
| MEDLINE | ID: mdl-30889381
12.
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
JCI Insight
; 52019 04 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30938714
13.
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
Cancer Immunol Res
; 7(7): 1047-1053, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31113804
14.
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Sci Transl Med
; 11(485)2019 03 27.
Artigo
Inglês
| MEDLINE | ID: mdl-30918115
15.
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.
Cell Rep
; 23(7): 2130-2141, 2018 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29768210
16.
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.
Nat Biotechnol
; 36(9): 847-856, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30102295
17.
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.
Sci Rep
; 7(1): 10541, 2017 09 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28874817
18.
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.
Oncoimmunology
; 4(3): e994446, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25949921